| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Ras
Antineoplaston A 10 targets Ras, a family of small GTPases that play a critical role in cell signaling and proliferation. It acts as an inhibitor (blocker/antagonist) of Ras. By inhibiting Ras, it may interfere with downstream signaling pathways that promote cancer cell growth and survival. It also induces apoptosis in human hepatoma cells. |
|---|---|
| ln Vitro |
In vitro, antineoplaston A10 inhibits the growth of human hepatoma cells by inducing apoptosis. It acts as a Ras inhibitor. Its antiproliferative effects have been demonstrated in various cancer cell lines. These activities support its potential as an anticancer agent.
|
| ln Vivo |
In vivo, antineoplaston A10 has been used in trials studying the treatment of various cancers, including sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer. However, its efficacy and safety remain controversial, with ongoing debates regarding its clinical benefits, and it has not been widely accepted in mainstream oncology.
|
| Enzyme Assay |
The in vitro binding/activity assay for antineoplaston A10 typically measures its ability to inhibit Ras activity. These assays can use purified Ras and measure its GTPase activity or its interaction with downstream effectors. Its effects on cell proliferation and apoptosis are assessed in cellular systems.
|
| Cell Assay |
In vitro cellular assays for antineoplaston A10 assess its antiproliferative and pro-apoptotic effects. Cancer cell lines are treated with antineoplaston A10, and cell viability, apoptosis, and Ras signaling are measured. These assays demonstrate the compound's functional activity in a relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for antineoplaston A10 have been conducted in models of various cancers to evaluate its efficacy. However, specific details of these studies are not extensively detailed in the available literature. Its clinical trials have been conducted in humans.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for antineoplaston A10 are not extensively detailed in the available literature. As a naturally occurring compound, its pharmacokinetic properties would be important for its in vivo efficacy. However, specific parameters such as half-life and bioavailability are not provided.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for antineoplaston A10 are not extensively detailed in the available literature. As a naturally occurring compound, it is generally considered to have low toxicity. However, its safety has been a subject of debate, and it has not been widely accepted in mainstream oncology.
|
| References | |
| Additional Infomation |
Antitumor agent A10 has been used in therapeutic trials for various cancers, including sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer. Antitumor agent A10 is a piperidine dione antitumor agent with potential antitumor activity. Originally isolated from human urine, it can now be synthesized artificially. This drug can intercalate into DNA, causing cell cycle arrest in the G1 phase, reducing mitosis, and decreasing protein synthesis. Antitumor agent A10 may also inhibit the expression of the ras oncogene and activate the tumor suppressor gene p53, thereby leading to cell differentiation and apoptosis. (NCI04)
Antineoplaston A 10 is a naturally occurring Ras inhibitor that has been studied for its potential anti-cancer effects. It has been used in trials for various cancers, including brain cancers like gliomas. Its efficacy and safety remain controversial. It is not approved for clinical use and is intended for research purposes only. |
| Molecular Formula |
C13H14N2O3
|
|---|---|
| Molecular Weight |
246.27
|
| Exact Mass |
246.1
|
| Elemental Analysis |
C, 68.74; H, 6.29; O, 24.97
|
| CAS # |
91531-30-5
|
| Related CAS # |
(Rac)-Antineoplaston A10;77658-84-5
|
| PubChem CID |
56260
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.266
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N([C@H]1CCC(=O)NC1=O)C(=O)CC1C=CC=CC=1
|
| InChi Key |
OQGRFQCUGLKSAV-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1
|
| Chemical Name |
N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide
|
| Synonyms |
ANP-A-10; ANPA-10; ANP A 10; ANPA 10
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 49~250 mg/mL (199.0~1015.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0606 mL | 20.3029 mL | 40.6058 mL | |
| 5 mM | 0.8121 mL | 4.0606 mL | 8.1212 mL | |
| 10 mM | 0.4061 mL | 2.0303 mL | 4.0606 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05498077 | Active Recruiting |
Procedure: Body scan meditation | Chronic Pain | Therapeutic Neuroscience Research Group |
May 1, 2021 | Not Applicable |
| NCT02887040 | Not yet recruiting | Drug: Atengenal Drug: Astugenal |
Brain Stem Glioma | Burzynski Research Institute | June 1, 2024 | Phase 3 |
| NCT05583955 | Active Recruiting |
Drug: NOE-105 Drug: Placebo |
Childhood-Onset Fluency Disorder |
Noema Pharma AG | July 25, 2022 | Phase 2 |
| NCT05533242 | Recruiting | Drug: Lu-177 labeled 6A10- Fab-fragments |
Glioblastom WHO Grade 4 | University Hospital Muenster | June 2023 | Phase 1 |
| NCT02864888 | Not yet recruiting | Radiation: Radiation Drug: Atengenal |
Brain Stem Glioma | Burzynski Research Institute | June 2024 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA